Comparative effects of doxazosin and carvedilol on clinical status and left ventricular function in hypertensive patients with mild heart failure

被引：0
作者：
Zacà F. [1 ,3 ]
Benassi A. [1 ]
Bolzani R. [2 ]
Ghidoni I. [2 ]
Santese G. [1 ]
Schipani A. [1 ]
Stefanio C. [1 ]
机构：
[1] Dipartimento di Cardiologia Medico-Chirurgica, Hesperia Hospital, Modena
[2] Dipartimento di Psicologia, University of Bologna, Bologna
[3] Modena
来源：
High Blood Pressure & Cardiovascular Prevention | 2005年 / 12卷 / 1期
关键词：
Enalapril; Carvedilol; Doxazosin; Target Blood Pressure; Negative Inotropic Effect;
D O I：
10.2165/00151642-200512010-00006
中图分类号：
学科分类号：
摘要：
Introduction: β-Blockers have been shown to be effective in the treatment of both arterial hypertension and heart failure. However, slow titration of β-blockers over several weeks and rigorous supervision are essential to minimise antiadrenergic adverse effects in patients with heart failure. α1-Blockers are well tolerated and effectively lower blood pressure by reducing peripheral resistance. Patients and methods: This study assessed changes in left ventricular function and quality of life in hypertensive patients with mild heart failure treated with enalapril and furosemide combined with a β-blocker with peripheral vasodilating activity (carvedilol) or an α-blocker (doxazosin), over a 1-year period. Sixty patients aged 45-65 years with untreated essential arterial hypertension and mild heart failure were randomised to receive enalapril + furosemide in combination with carvedilol or doxazosin. Results: In the carvedilol compared with the doxazosin group, ejection fraction diminished significantly (38% vs 42%, p < 0.05) and quality of life worsened significantly (Minnesota Living Heart Failure score 54 vs 47, p < 0.05) during the first 3 weeks of treatment. Ejection fraction and quality of life had significantly improved from baseline in both groups by 12 months. Conclusion: Doxazosin in combination antihypertensive therapy rapidly improves clinical status and haemodynamics in hypertensive patients with mild heart failure by reducing afterload. After 1 year, doxazosin and carvedilol improve clinical and haemodynamic parameters. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码：37 / 44
页数：7
相关论文
共 37 条
  • [1] Levy D., Larson M.G., Vasan R.S., Et al., The progression from hypertension to congestive heart failure, JAMA, 275, pp. 1557-1562, (1996)
  • [2] Chobanian A.V., Bakris G.L., Black H.R., Et al., The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report, JAMA, 289, pp. 2560-2572, (2003)
  • [3] 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, J Hypertens, 21, pp. 1011-1053, (2003)
  • [4] Zanchetti A., What have we learned and what haven't we from clinical trials on hypertension?, Hypertension: Pathophysiology, Diagnosis, and Management, pp. 2509-2529, (1995)
  • [5] Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg, JAMA, 202, pp. 1028-1034, (1967)
  • [6] Hansson L., Lindholm L.H., Niskanen L., Et al., Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The CAptopril Prevention Project (CAPPP) randomised trial, Lancet, 353, pp. 611-616, (1999)
  • [7] Yusuf S., Sleight P., Pogue J., Et al., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study investigators, N Engl J Med, 342, pp. 145-153, (2000)
  • [8] Psaty B.M., Smith N.L., Siscovick D.S., Et al., Health outcomes associated with antihypertensive therapies used as first-line agents: A systematic review and meta-analysis, JAMA, 277, pp. 739-745, (1997)
  • [9] Tepper D., Frontiers in congestive heart failure: Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF), Congest Heart Fail, 5, pp. 184-185, (1999)
  • [10] Packer M., Coats A.J., Fowler M.B., Et al., Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, pp. 1651-1658, (2001)
1234